Virus-like particles (VLPs) are a group of subunit vaccines, which due to a stronger protective immunogenicity, aredistinguished from soluble recombinant antigens. Like nativeviruses, virus-like particles can be both enveloped and nonenveloped. They are formed from the expression of one or moreviral structural proteins in a heterologous system. Depending onthe complexity of the VLP, the proteins can be produced inprokaryotic or eukaryotic expression systems, or in certaincases, they can be manufactured and assembled in the cell-freeconditions. Virus-like particles can be produced in a range ofcell culture systems, including mammalian cell lines, insectcells, yeast, plant cells and cell-free conditions. To date, a widerange of VLP-based vaccine candidates against viral, bacterial, parasitic, and fungal pathogens, as well as non-infectiousdiseases, have been produced in various expression systems. Some of VLPs have entered clinical development and few ofthem have licensed and commercialized.